Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

Vivani Medical (Nasdaq:VANI) announced that it filed a Form 10 registration statement with the SEC to spin off its ...

Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for ...

Detailed price information for Clearside Biomedi (CLSD-Q) from The Globe and Mail including charting and trades.

Quantum computing has been lurking in the background for years. Discover 5 cutting-edge science sectors like CRISPR and ...

May 13, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, ultra long-acting drug implants, today reported ...

You can claim eligible medical expenses on line 33099 or line 33199 of your tax return (Step 5 – Federal tax). Line 33099 – Medical expenses for self, spouse or common-law partner, and your dependant ...

Vivani Chief Executive Officer Adam Mendelsohn, Ph.D., stated, "Our ongoing first-in-human study, LIBERATE-1, remains on track to deliver key data in mid-2025 with the aim of validating our ...

A diagnostic medical sonographer could be answering the question "Is it a boy or a girl?" as well as a host of other life-changing medical questions with the help of ultrasound technology.

All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1 study in obese or overweight individuals; top ...